EP4051297A4 - Generation of cd38 knock-out primary and expanded human nk cells - Google Patents

Generation of cd38 knock-out primary and expanded human nk cells Download PDF

Info

Publication number
EP4051297A4
EP4051297A4 EP20882013.4A EP20882013A EP4051297A4 EP 4051297 A4 EP4051297 A4 EP 4051297A4 EP 20882013 A EP20882013 A EP 20882013A EP 4051297 A4 EP4051297 A4 EP 4051297A4
Authority
EP
European Patent Office
Prior art keywords
knock
cells
generation
out primary
expanded human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20882013.4A
Other languages
German (de)
French (fr)
Other versions
EP4051297A1 (en
Inventor
Dean Anthony LEE
Meisam Naeimi KARAROUDI
Gabriel Ghiaur
Yuya Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Research Institute at Nationwide Childrens Hospital
Original Assignee
Johns Hopkins University
Research Institute at Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Research Institute at Nationwide Childrens Hospital filed Critical Johns Hopkins University
Publication of EP4051297A1 publication Critical patent/EP4051297A1/en
Publication of EP4051297A4 publication Critical patent/EP4051297A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464426—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
EP20882013.4A 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells Pending EP4051297A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928524P 2019-10-31 2019-10-31
PCT/US2020/058565 WO2021087466A1 (en) 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells

Publications (2)

Publication Number Publication Date
EP4051297A1 EP4051297A1 (en) 2022-09-07
EP4051297A4 true EP4051297A4 (en) 2023-10-18

Family

ID=75715400

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20882013.4A Pending EP4051297A4 (en) 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells

Country Status (11)

Country Link
US (1) US20220401482A1 (en)
EP (1) EP4051297A4 (en)
JP (1) JP2022554284A (en)
KR (1) KR20220093337A (en)
CN (1) CN114867485A (en)
AU (1) AU2020375053A1 (en)
BR (1) BR112022008215A2 (en)
CA (1) CA3156509A1 (en)
IL (1) IL292584A (en)
MX (1) MX2022005051A (en)
WO (1) WO2021087466A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CA3225985A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023081200A2 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
WO2023080210A1 (en) * 2021-11-05 2023-05-11 学校法人東海大学 Identification of treatment target in aggressive nk leukemia
WO2023172917A1 (en) 2022-03-07 2023-09-14 Sanofi-Aventis U.S. Llc Use of isatuximab in combination with other agents for the treatment of multiple myeloma
CN114921416B (en) * 2022-05-12 2023-05-23 广东普罗凯融生物医药科技有限公司 NK cell and preparation method thereof
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
CN116679065B (en) * 2023-07-31 2023-11-14 北京大学人民医院 Application of detection reagent, method for predicting prognosis of multiple myeloma treatment and product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454871B1 (en) * 2016-12-09 2019-06-26 Onkimmune Limited Engineered natural killer cells and uses thereof
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
MA42895A (en) * 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
WO2017127755A1 (en) * 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454871B1 (en) * 2016-12-09 2019-06-26 Onkimmune Limited Engineered natural killer cells and uses thereof
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021087466A1 *
YUFENG WANG ET AL: "Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo –Expanded Autologous NK Cells", CLINICAL CANCER RESEARCH, vol. 24, no. 16, 17 April 2018 (2018-04-17), US, pages 4006 - 4017, XP055510761, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-3117 *

Also Published As

Publication number Publication date
CN114867485A (en) 2022-08-05
BR112022008215A2 (en) 2022-07-12
AU2020375053A1 (en) 2022-05-26
KR20220093337A (en) 2022-07-05
WO2021087466A1 (en) 2021-05-06
EP4051297A1 (en) 2022-09-07
CA3156509A1 (en) 2021-05-06
MX2022005051A (en) 2022-08-08
US20220401482A1 (en) 2022-12-22
JP2022554284A (en) 2022-12-28
IL292584A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
EP4051297A4 (en) Generation of cd38 knock-out primary and expanded human nk cells
EP3796924A4 (en) Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
EP3911718A4 (en) Use of renewable energy in olefin synthesis
WO2020047004A3 (en) Methods of generating an array
EP3430132A4 (en) Generation of midbrain-specific organoids from human pluripotent stem cells
EP4010839A4 (en) Systems and methods of controllable natural language generation
EP3898692A4 (en) Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
EP3752602A4 (en) Method for generating cells of the t cell lineage
EP3740186A4 (en) Hygiene product pod and methods of using same
EP3532605A4 (en) Improved generation of muscle lineage cells and therapeutic uses thereof
EP3827075A4 (en) Nef-containing t cells and methods of producing thereof
EP3884060A4 (en) Integration of fermentation and gasification
EP3420075A4 (en) Generation of cancer stem cells and use thereof
EP3772039A4 (en) Generation of dynamic picture
EP3685379A4 (en) Multi-bias level generation and interpolation
EP4048402A4 (en) Modified cytotoxic t cells and methods of use thereof
WO2018146679A3 (en) Photoreceptor cells for the treatment of retinal diseases
EP3976066A4 (en) Methods of generating and expanding hematopoietic stem cells
EP3873229A4 (en) Rice bran extract compositions, methods of making and using same
EP3691660A4 (en) Expansion and use of expanded nk cell fractions
EP3941631A4 (en) Isolation of single cells and uses thereof
EP3840769A4 (en) Cyclosporine compositions and methods of use
EP3700334A4 (en) Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
EP4062269A4 (en) Dynamic modification of multiple haptic effects
EP3790589A4 (en) Stem cell-derived alpha cells and methods of generating same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE JOHNS HOPKINS UNIVERSITY

Owner name: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAGAI, YUYA

Inventor name: GHIAUR, GABRIEL

Inventor name: KARAROUDI, MEISAM NAEIMI

Inventor name: LEE, DEAN ANTHONY

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079783

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20230918

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230912BHEP

Ipc: C12N 15/86 20060101ALI20230912BHEP

Ipc: C12N 5/0783 20100101ALI20230912BHEP

Ipc: A61K 35/17 20150101AFI20230912BHEP